 "Claris Lifesicences gains on settlement with Fresenius Kabi USA")
Claris Lifesicences has moved higher by 6% at Rs 328 on the BSE after it announced settlement of litigation and license agreement for its generic DIPRIVAN in USA.
“The company has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc. with reference to alleged infringement of a patent relating to propofol for injection, 10 mg/ml, which is a generic version of DIPRIVAN,” Claris Lifesicences said in a press release.
Under the terms of the settlement and license agreement, Claris and Claris Lifesciences Inc. (USA) has been granted approval to sell its generic version of propofol for injection beginning 15th October 2016, prior to 1st June 2025 expiry of the patent that formed the basis of the litigation, it added.
Propofol Injection had an annual market size of approximately US$ 251 million in the USA, according to IMS health data as of June 2014.
The stock opened at Rs 334 and has seen around 356,000 shares changed hands on the counter till 1032 hours on the BSE.
“The company has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc. with reference to alleged infringement of a patent relating to propofol for injection, 10 mg/ml, which is a generic version of DIPRIVAN,” Claris Lifesicences said in a press release.
Under the terms of the settlement and license agreement, Claris and Claris Lifesciences Inc. (USA) has been granted approval to sell its generic version of propofol for injection beginning 15th October 2016, prior to 1st June 2025 expiry of the patent that formed the basis of the litigation, it added.
Propofol Injection had an annual market size of approximately US$ 251 million in the USA, according to IMS health data as of June 2014.
The stock opened at Rs 334 and has seen around 356,000 shares changed hands on the counter till 1032 hours on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%